Research programme: immune-mediated disease therapeutics - Sanofi/UCB
Latest Information Update: 12 Mar 2014
At a glance
- Originator Sanofi; UCB
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 12 Mar 2014 Early research in Immunological disorders in France and Belgium (unspecified route)